Copy to clipboard 
Evonik’s VECOLLAN recombinant, non-animal-derived collagen-like protein platform is now available in a grade suitable for use in clinical trials. The new grade marks a significant process scale-up milestone for this new biomaterial, supporting the development of medical devices that improve safety and performance for patients.
The new clinical-grade VECOLLAN is an innovation in biosynthetic processing, enabling advancements in various medical fields. Notably, forms of VECOLLAN such as sponges and hydrogels have shown particular promise in applications including orthopedics and sports medicine.
Evonik is set to offer partners validated material in 2026. The recombinant collagen-like protein is produced through a sustainable fermentation-based process that ensures high purity and consistency, addressing common concerns associated with animal-derived collagens, such as variability and potential allergic reactions.
With its tunable properties and compatibility with widely used processing technologies, VECOLLAN is a safe and sustainable alternative for the medical device industry.
“Our new VECOLLAN grade is another step forward in our mission to provide high-quality, non-animal-derived collagen alternatives for medical applications and to push the boundaries of medical technology. Now, we are actively seeking collaborations with partners to facilitate entry into clinical trials,” said Jeff Smith, head of medical devices at Evonik’s Health Care business line.
Source: Evonik
